轩竹生物制药有限公司(简称“轩竹生物-B”)近日获得监管批准,将正式启动其核心产品安纳拉唑钠用于幽门螺杆菌根除治疗的III期临床试验。该阶段试验的启动标志着药物研发进程迈入关键一步,旨在进一步验证其在根除幽门螺杆菌方面的有效性与安全性。
轩竹生物制药有限公司(简称“轩竹生物-B”)近日获得监管批准,将正式启动其核心产品安纳拉唑钠用于幽门螺杆菌根除治疗的III期临床试验。该阶段试验的启动标志着药物研发进程迈入关键一步,旨在进一步验证其在根除幽门螺杆菌方面的有效性与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.